Based on the mutual synergistic antitumor effects, the Impower150 trial further explored that chemotherapy + immunotherapy + anti-angiogenic therapy as first-line therapy in NSCLC patients with EGFR mutations possessed better clinical efficacy than chemotherapy + immunotherapy and chemotherapy + anti-angiogenic therapy, despite the greater toxicity effects [20]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.